DigestRedComo funciona
Red
/
Empresas
Af
No verificado

Affinia Therapeutics

Sobre qué escribimos

BiotecnologíaCardiologíaCienciaFarmacéuticaSalud

11 Comunicados de prensa

Ver todos los comunicados de prensa
28/04/2026
Eventos
Salud
Biotecnología
Ciencia
Farmacéutica
Cardiología
Affinia Therapeutics to Present AFTX-201 for BAG3-Associated Dilated Cardiomyopathy (DCM) and Highlight Proprietary Capsid Engineering and Manufacturing Data at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Fuente
Affinia Therapeutics
Editor
Business Wire
1.00
0
06/04/2026
Industria
Ciencia
Sanidad
Farmacéutica
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Cardiología
Higiene alimentaria
Salud
Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)
Fuente
Affinia Therapeutics
Editor
Business Wire
1.00
0
04/03/2026
Industria
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Cardiología
Salud
Farmacéutica
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)
Fuente
Affinia Therapeutics
Editor
Business Wire
1.00
0
18/02/2026
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Cardiología
Salud
Farmacéutica
Industria
Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)
Fuente
Affinia Therapeutics
Editor
Business Wire
1.00
0
04/02/2026
Industria
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Cardiología
Salud
Farmacéutica
Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)
Fuente
Affinia Therapeutics
Editor
Business Wire
1.00
0
14/10/2025
Asociaciones/Profesionales
Salud
Biotecnología
Sanidad
Finanzas
Farmacéutica
Cardiología
Eventos
Affinia Therapeutics to Participate in Upcoming Investor Conferences
Fuente
Affinia Therapeutics
Editor
Business Wire
1.00
0
07/10/2025
Salud
Técnica
Biotecnología
Medicina - Varios
Cardiología
Affinia Therapeutics Announces Series C Financing to Advance New Class of Gene Therapies Intended to Provide Improved Safety and Efficacy
Fuente
Affinia Therapeutics
Editor
Business Wire
1.00
0
03/06/2025
Ciencia
Biotecnología
Cardiología
Asociaciones/Profesionales
Farmacéutica
Salud
Mercado laboral
Affinia Therapeutics and DCM Foundation Announce Partnership to Increase Awareness About BAG3 Dilated Cardiomyopathy and Critical Need for Genetic Testing to Help Save Lives
Fuente
Affinia Therapeutics
Editor
Business Wire
1.00
0
13/05/2025
Eventos
Industria
Cardiología
Biotecnología
Higiene alimentaria
Salud
Sanidad
Farmacéutica
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Affinia Therapeutics Presents New Data on its Lead AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th American Society of Gene & Cell Therapy 2025 Annual Meeting
Fuente
Affinia Therapeutics
Editor
Business Wire
1.00
0
28/04/2025
Industria
Ciencia
Biotecnología
Medicina - Varios
Cardiología
Salud
Farmacéutica
Affinia Therapeutics to Present New Data on its AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th Annual American Society of Gene & Cell Therapy 2025 Annual Meeting
Fuente
Affinia Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0